Legal expert in health care, partner, and cochair of the health care coverage and reimbursement practice at Foley Hoag LLP, Ross Margulies discusses his excitement and expectations as a featured speaker at the upcoming 2024 AMCP Annual Conference.
The Academy of Managed Care Pharmacy (AMCP) is hosting its annual conference in New Orleans this year from April 15-18, and will be attracting over 4000 attendees.
One of the featured speakers is Ross Margulies, a health care attorney and partner at Foley Hoag LLP. Margulies will be focusing on health care reform and its impact on pharmacy benefit managers (PBMs). In this interview, he shares his expectations for the conference and the key takeaways he hopes attendees will gain.
Transcript
What are you looking forward to most at AMCP?
I've been to AMCP conferences many times over the last 6 or 7 years probably. Frankly, what I love about AMCP is it's one of the few forums where you get together different stakeholders, pharmacies, managed care pharmacies, community pharmacies, PBMs, manufacturers, and you talk about some of the tough issues. I'm talking about one of them, which is PBM reform. You know, it's pretty rare these days that you get diverse perspectives, and I honestly think a lot of really interesting conversations happen because of that.
What are you hoping attendees can take away from the meeting this year?
With respect to PBM reforms, I'd like my attendees to know what Congress is considering because it's filled with a lot of jargon, it’s very confusing. But I think the chance that there is going to be some type of PBM reform is pretty likely. No matter where you are on the drug supply chain, understanding what those provisions are and how they impact you is going to be really necessary, so that's my goal.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More